Vaxart (VXRT) reported a Q1 net loss late Tuesday of $0.07 per diluted share, narrowing from the loss of $0.14 a year earlier.
Two analysts polled by FactSet expected a loss of $0.07.
Revenue in the three months ended March 31 rose to $20.9 million from $2.18 million a year earlier.
The company had cash, cash equivalents and investments of $41.9 million as of March 31 with a cash runway expected into Q1 2026.
Vaxart appointed Jeroen Grasman as chief financial officer, effective May 19. He succeeds Phillip Lee, who resigned for personal reasons, the company said.
Grasman most recently was CFO at AltruBio.
Vaxart shares rose 5.9% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.